Sprint Bioscience AB (DE:5JA1)

FRANKFURT:5JA1

5JA1

Sprint Bioscience AB

RESEARCH TOOLSreports

Sprint Bioscience AB (5JA1) Price & Analysis

0 Followers

5JA1 Stock Chart & Stats

€0.11

>-€0.01(-2.52%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-2.52%)

Day’s Range― - ―

52-Week Range€0.02 - €0.24

Previous CloseN/A

Volume0.00

Average Volume (3M)83.00

Market Cap

€24.15M

Enterprise Value€137.08M

Total Cash (Recent Filing)€126.70M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)1.5

Beta1.79

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding105,515,540

10 Day Avg. Volume250

30 Day Avg. Volume83

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€9.38M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt reduces refinancing and interest burdens, preserving financial flexibility for licensing negotiations or selective R&D spend. A clean balance sheet supports durable viability through biotech cycle fluctuations and makes partnership funding less constrained over the next 2–6 months.

2025 Revenue And Profitability InflectionA clear swing to material revenue growth and profitability signals successful de-risking of programs or milestone monetization. This lasting improvement strengthens internal cash generation and credibility with partners, helping sustain business development and licensing activity.

Partnering/licensing Business ModelA licensing-focused model limits capital intensity by transferring late-stage development risk to partners and creates multiple non-dilutive cash inflection points (upfronts, milestones, royalties). This structural model supports steady long-term cash event potential without large clinical spend.

Bears Say

High Earnings VolatilityWide swings in profitability reflect milestone-driven and lumpy revenue recognition, making future earnings and planning uncertain. For partners and investors, this reduces predictability of sustainable cash flows and complicates budgeting, hiring, and multi-program development decisions.

Uneven Cash Generation / LumpinessDependence on milestone and licensing receipts produces irregular operating cash flow, increasing the chance of funding gaps between deals. That structural lumpiness can force opportunistic capital raises or compress program timelines, creating execution risk over the medium term.

Small Scale And Prior Weak CapitalizationA small headcount and history of low equity constrain the firm's capacity to progress multiple discovery programs simultaneously and heighten vulnerability to single-program setbacks. Limited scale raises reliance on partners and external funding for sustained pipeline advancement.

5JA1 FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was €0.02 and its highest was €0.24 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is €24.15M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 37 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported €0.098 earnings per share for the quarter, beating the consensus estimate of N/A by €0.098.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of €0.098 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.614%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in DE:5JA1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.